Les Laboratoires Medis
Les Laboratoires Medis is a limited company under Tunisian law
with a mandate to manufacture and market various generic medications. It is
founded in 1995 under the vision of Dr Lassaad Boujbel to create a quality
manufacturing facility to serve the Tunisian people and the region.
Les Laboratoires Medis started on February 2000 and currently has a broad portfolio of over 250 quality products. The Tunisian campus has different manufacturing facilities, as injectable plants, solid dosage form and DPI plants.
The company produces liquid and lyophilised injectables, dental cartridges and prefilled syringes, capsule and tablet and dry powder inhalers.
Les Laboratoires Medis has a new state of the art high-containment facility that started operations at the beginning of this year 2019 to manufacture high potent and oncology drugs to ensure availability of high-quality oncology generics to north Africa and the region.
Les Laboratoires Medis is building a new facility for LPV (large parenteral volume) that planned to start operations by Q1 2020.
The headquarters of Les Laboratoires Medis includes research and development, procurement, human resources and all other services associated with the production and marketing of our products such as quality assurance, control management, regulatory affairs and export services.
The company now employs over 700 skilled and dynamic people with more than 30 employees in the research and development department that includes pharmacists, engineers and chemists and more than 150 workers in the marketing and sales team.
Les Laboratoires Medis has built a solid reputation in the Tunisian pharmaceutical industry for its expertise in developing world-class products, combined with marketing and more effective sales strategies and now it is the leader of the Tunisian pharmaceutical industry over the past five years.
|Affiliated categories:||Biosimilars |Injectables |Parenterals More|
Our Top products
BORTESOMIB NEAPOLIS (bortezomib)
Bortezomib NEAPOLIS for Injection is an antineoplastic agent
available for intravenous injection (IV) use only.
Each single dose vial contains 3.5 mg of Bortezomib as a sterile lyophilized powder
ENOXA (enoxaparin sodium)
ENOXA is a Low Molecular Weight Heparin, in a prefilled seringe. It is the first product in sales in TunisiaMore info
EPOMAX 2000 (RECOMBINANT HUMAN ERYTHROPOEITIN ALPHA? 2000 UI / 1 ml)
After granting the Marketing Authorization of THE FIRST
Human Recombinant alpha Erythropoietin (EPO), MédiS becomes the FIRST Tunisian
pharmaceutical company to produce and market its biosimilar EPO commercially
appointed as EPOMAX®.
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation